글로벌 Q-열 치료 시장 – 2030년까지의 산업 동향 및 예측

Q열 치료제 시장 분석 및 규모

2020년 국립의학도서관(NLM)이 발표한 보고서에 따르면, 매년 10만 명 중 약 50명이 급성 Q열에 시달리고, 100만 명 중 1명이 1년 동안 만성 Q열에 걸린다고 합니다. 전 세계적으로 급성 Q열 환자 풀이 증가하는 것을 목격할 수 있습니다. WHO의 통계에 따르면, 2017년 전 세계 1인당 의료비 지출은 1,064.741달러였습니다.

Data Bridge Market Research는 2022년에 46억 2,305만 달러였던 Q-열 치료 시장이 2030년까지 67억 7,840만 달러에 도달할 것으로 분석했으며, 2023년부터 2030년까지의 예측 기간 동안 연평균 성장률은 4.90%에 이를 것으로 예상합니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

Q-열병 치료 시장 범위 및 세분화  

시장 정의

Q열은 쿼리열이라고도 알려져 있습니다. 이것은 Coxiella burnetiid 박테리아에 의해 발생하는 박테리아 감염의 한 유형입니다. 이 열을 일으키는 박테리아는 전 세계적으로 소, 양, 염소와 같은 동물에서 발견됩니다. 많은 환자가 전혀 증상을 보이지 않지만 어떤 경우에는 감염이 수년 후에 재발할 수 있습니다. 만성 Q열은 심장, 뇌, 폐에 손상을 줄 수 있고 어떤 경우에는 당뇨병을 일으킬 수 있는 더 독성이 강한 Q열의 한 형태입니다.  

Q열 치료제 시장 동향

운전자

• Q열 환자 증가

질병통제예방센터(CDC)가 발표한 자료에 따르면, 2019년 미국에서 급성 Q열이 178건, 만성 Q열이 34건 발생한 것으로 나타났습니다. 국립의학도서관(NLM)이 2020년에 발표한 보고서에 따르면, 10만 명 중 약 50명이 매년 급성 Q열을 앓고, 100만 명 중 1명이 1년 동안 만성 Q열을 앓는다고 합니다. 또한, 농장 노동자, 면역력이 약한 사람, 노령층 등은 Q열에 걸릴 가능성이 더 높습니다.

• 조직 간 파트너십 확대

여러 시장 참여자 간의 증가하는 파트너십 또는 협업은 시장 성장을 촉진하고 있습니다. 예를 들어, Basilea Pharmaceutica Ltd.는 Shenzhen China Resources Gosun Pharmaceuticals Co. Ltd.와 파트너십을 맺고 Basilea의 항생제 Zevtera에 대한 중국 국가의약품감독청의 약물 승인 허가를 받았습니다.

기회

• 증가하는 의료비 지출

As per the statistics by the WHO, the global per capita healthcare expenditure resulted to USD 1,064.741 in the year 2017. The global healthcare expenditure per person increase from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country which amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. Furthermore, according to the projections by the Centres for Medicare & Medicaid Services (CMS), the projected average annual percent change associated with National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Moreover, the National Health Expenditures are expected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. This factor is helping in increasing the market growth.

Restraints/Challenges

• Lack of Awareness About Q-fever

Not much awareness about the disease can lead to the restriction of the market growth. Q-fever is not commercially popular; thus, people are not much aware of that. Thus, it hampers the market growth.

This Q-fever treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Q-fever treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In 2022, Pfizer Inc. and Myovant Science released an update regarding MYFEMBREE, a 1 mg drug for the treatment of severe pain, where they have stated that U.S. FDA has extended the period to review this drug.
• In 2022, Sanofi announced the launch of its Foundation S with the aim to develop a healthy and useful future for the current and upcoming generations.
• In 2022, Basilea Pharmaceutical launched its first-in-class antifungal program for providing necessary help to patients who are suffering from fungal and bacterial infection and cancer

Global Q-fever Treatment Market Scope

The Q-fever treatment market is segmented on the basis of type, treatment type, drugs, vaccines, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Acute Q-Fever
• Chronic Q-Fever

Treatment Type

• Medication
• Vaccinations
• Surgery

Drugs

• Doxycycline
• Ciprofloxacin
• Pefloxacin
• Others

Vaccines

• Live Attenuated Vaccine
• Purified Corpuscular Formalin-Inactivated Vaccine
• Soluble Vaccine
• Others

End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Q-fever Treatment Market Regional Analysis/Insights

The Q-fever treatment market is analyzed and market size insights and trends are provided by type, treatment type, drugs, vaccines, end user and distribution channel as referenced above.

The countries covered in the Q-fever treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific dominates the Q-fever treatment market because of the rise in the occurrence of chronic diseases such as cancer, diabetes, and bacterial infection in developing countries. 

North America is expected to witness significant amount of growth in the Q-fever treatment market because of the rise in the acceptance of pets. Additionally, the upsurge in the preventive treatments and care facilities for companion animals is further predicted to boost the growth of the Q-fever treatment market in the region in the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Q-fever Treatment Market Share Analysis

The Q-fever treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Q-fever treatment market.

Some of the major players operating in the Q-fever treatment market are:

• EpiVax, Inc.(U.S.)
• GSK plc (U.K.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Sanofi (France)
• Bayer AG (Germany)
• Amway Corp. (U.S.)
• Zydus Group (India)
• Lilly (U.S.)
• Pfizer Inc. (U.S.)
• Abbvie Inc. (미국)
• 브리스톨 마이어스 스퀴브 회사(미국)
• 애벗(미국)
• 머크앤코(미국)
• 마일런 NV(미국)
•  루팡(인도)
• Sun Pharmaceutical Industries Ltd. (인도)
• Amneal Pharmaceuticals LLC. (미국)
• Aurobindo Pharma(인도)
• Teva Pharmaceutical Industries Ltd(이스라엘)
• Mayne Pharma Group Limited(호주)
• Alembic Pharmaceuticals Limited(인도)
• 노바티스 AG(스위스)
• 야시카 제약 주식회사(인도)
• 바실리아 파마슈티카 유한회사(스위스)

SKU-46698